Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2018. Module: SNOMED CT core
Descriptions:
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
collyre en suspension | est un(e) (attribut) | Eye suspension | false | Inferred relationship | Some | ||
collyre en suspension | est un(e) (attribut) | Eye drops | true | Inferred relationship | Some | ||
collyre en suspension | Has dose form administration method (attribute) | Instill | true | Inferred relationship | Some | ||
collyre en suspension | Has dose form intended site (attribute) | Ocular (intended site) | true | Inferred relationship | Some | ||
collyre en suspension | Has dose form release characteristic (attribute) | Conventional release (release characteristic) | true | Inferred relationship | Some | ||
collyre en suspension | Has basic dose form (attribute) | Suspension | true | Inferred relationship | Some | ||
collyre en suspension | Has dose form transformation (attribute) | No transformation | true | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Product containing precisely prednisolone acetate 1.2 milligram/1 milliliter conventional release suspension for eye drops (clinical drug) | a une forme pharmaceutique (attribut) | False | collyre en suspension | Inferred relationship | Some | |
Dexamethasone 500 microgram/mL and tobramycin 3 mg/mL eye suspension | a une forme pharmaceutique (attribut) | False | collyre en suspension | Inferred relationship | Some | |
Besifloxacin 6 mg/mL eye suspension | a une forme pharmaceutique (attribut) | False | collyre en suspension | Inferred relationship | Some |
Reference Sets
Canada English language reference set (foundation metadata concept)